GET DAILY SIGNALSCrescent Biopharma (CBIO) Q3 2026 Earnings: Focus on Cash Runway and Pipeline Updates
Key Takeaways
- Crescent Biopharma, Inc. (CBIO) is expected to report third-quarter 2026 results on or around November 5, 2026, after the market close.
- Wall Street consensus calls for a net loss of roughly $0.67 per share, narrowing from a loss of $1.27 per share in the same quarter last year.
- Consensus revenue is minimal at approximately $0.36 million, reflecting the company's clinical-stage, pre-commercial status.
- Investors will focus on the company's cash runway (about $171.6 million as of June 30, 2026) and progress on lead oncology candidate CR-001.
- Analysts remain broadly constructive, with a Strong Buy consensus and an average 12-month price target near $31.50.
Earnings Context and Why It Matters
As a clinical-stage biotechnology company, Crescent Biopharma does not yet generate meaningful product revenue, so its quarterly report serves primarily as a progress check on drug development and capital efficiency. The company, formerly known as GlycoMimetics, is advancing CR-001, an anti-PD-1 (programmed cell death protein 1) / anti-VEGF (vascular endothelial growth factor) bispecific antibody in Phase 3 development for solid tumors. With losses expected to continue in the near term, the market's attention centers on cash runway, trial timelines, and the company's strategic partnership with Sichuan Kelun-Biotech. The upcoming report will help investors gauge whether the pipeline is advancing on schedule and whether the balance sheet can support operations through key clinical milestones. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect Crescent Biopharma to post a third-quarter 2026 loss of approximately $0.67 per share, according to consensus estimates, compared with a loss of $1.27 per share in the third quarter of 2025. Individual estimates range from a loss of about $0.53 to $0.85 per share. Consensus revenue is minimal at roughly $0.36 million, consistent with a pre-revenue biotechnology business. For context, the company reported a loss of $0.74 per share in the second quarter of 2026, roughly in line with expectations, and has beaten consensus earnings per share (EPS) in three of its last eight quarters. Because near-term revenue is negligible, investors will watch operating expenses, research and development (R&D) spending, and cash burn more closely than the top line.
Market Reaction and Investor Sentiment
Sentiment heading into the third-quarter report is cautiously optimistic but heavily dependent on pipeline execution rather than financial results. Crescent Biopharma shares have been volatile over the past year, trading within a wide range, and analyst coverage remains skewed positive with a Strong Buy consensus. The key risk heading into earnings is any signal that the CR-001 Phase 3 program has been delayed or that cash burn is accelerating faster than expected. With minimal revenue to anchor the story, the market's reaction will likely hinge on management's commentary about clinical timelines, partnership milestones, and the remaining cash runway rather than the reported loss figure itself. From what I see, this is important because pipeline updates often drive the real moves in names like this.
Forward Outlook and Key Factors to Monitor
Following the third-quarter update, investors should watch several forward-looking factors. First, clinical execution on CR-001 remains the central driver: any updates on enrollment, data readouts, or regulatory interactions for the Phase 3 solid-tumor program will carry outsized weight relative to near-term financial metrics.
Second, capital position matters. With roughly $171.6 million in cash and investments as of mid-2026, the company's ability to fund its pipeline through key milestones without excessive dilution will be closely scrutinized. Watch management's commentary on expected cash runway and any plans for future financing.
Third, the strategic collaboration with Kelun-Biotech could shape both development economics and future milestone potential, so any update on partnership progress is worth monitoring. Finally, investors should track R&D expense trends and any shifts in the broader oncology funding environment, which can influence both sentiment and the company's strategic options. As always with early-stage biotechs, results should be viewed through the lens of pipeline progress and cash sustainability rather than near-term profitability. I'm watching this closely as the data emerges.
Using AI Tools in Biotech Research
In my own analysis, I turn to Tickeron’s AI Screener to quickly compare CBIO against peers in the biotechnology sector. It helps filter for technical patterns, fundamentals, and AI-driven signals that highlight comparable setups or emerging opportunities. This kind of structured scanning supports a more efficient review of the broader landscape without replacing fundamental due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CBIO in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2026
CBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 40 cases where CBIO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CBIO's RSI Oscillator exited the oversold zone, 31 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for CBIO just turned positive on October 21, 2026. Looking at past instances where CBIO's MACD turned positive, the stock continued to rise in 31 of 38 cases over the following month. The odds of a continued upward trend are 82%.
Following a +7.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBIO advanced for three days, in 194 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 52 cases where CBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CBIO as a result. In 89 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 50-day moving average for CBIO moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CBIO entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.018) is normal, around the industry mean (2.788). CBIO has a moderately low P/E Ratio (-92.429) as compared to the industry average of (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (35.461) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 53 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. CBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage biopharmaceutical company
Industry Biotechnology
Advertisement